Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative

Patricia Esperón1,2, Matías F. Martínez2,3, María A. Redal2,4, Alberto Lazarowski2,5, Andrés López-Cortés5, Nelson M. Varela2,3 and Luis A. Quiñones2,3*

1Molecular Genetics Laboratory, Clinical Biochemistry Department, School of Chemistry, Universidad de la República, Montevideo, Uruguay, 2Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain, 3Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile, 4Genetic Division, Department of Medicine, INFIBIOC, Hospital de Clínicas José de San Martín, Buenos Aires University, Buenos Aires, Argentina, 5Clinical Biochemistry Department, Hospital de Clínicas José de San Martín School of Pharmacy and Biochemistry, Institute for Research in Physiopathology and Clinical Biochemistry (INFIBIOC), University of Buenos Aires, Buenos Aires, Argentina

Keywords: pharmacogenetics, pharmacogenomics, CYTED, Latin America, precision medicine

Editorial on the Research Topic

Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative

INTRODUCTION

Since the pharmacogenetics and pharmacogenomics (PGx) field started to rise, the information about the relationship between actionable genes, genotypes, and response to drugs has increased exponentially (Nicholson et al., 2021). There is evidence of the utility and impact of genetics in the choice of therapeutic regimens improving their effectiveness and safety (Arbitrio et al., 2021). Even some international efforts have created clinical guidelines that allow the implementation of pharmacogenomics in daily clinical practice. In addition to clinical outcomes, Economic benefits have been associated with the translation from “the bench to the bedside”.

Moreover, several major PGx expert organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC, 2021) and the Dutch Pharmacogenetics Working Group (DPWG), provide gene-drug guidelines for actionable variants. In addition, Ubiquitous Pharmacogenomics (U-PGx, 2021), the Latin American Network for the Implementation and Validation of Pharmacogenomics Guidelines (RELIVAF-CYTED, 2021), and the Southeast Asian Pharmacogenomics Research Network (SEAPharm, Chumnumwat et al., 2019) have investigated pharmacotherapeutic recommendations guided by pharmacogenetics. In this respect, based on scientific evidence the Food and Drug Administration (FDA) has published a list of PGx biomarkers for drug labelling (FDA, 2021).

Even though high-quality research addresses the utility of implementing pharmacogenetics programs in clinical practice, most of this evidence comes from the United States or Europe. Moreover, commonly, it does not include the Latin American population, or when the guidelines do, it is considering as one big group. Some recently regional formed scientific societies (RELAGH,
2014; SOLFAGEM, 2021) and international efforts (RELIVAF-CYTED) are looking to shorten the region’s gap of evidence and information. In this respect, Latin America is a vast region with some characteristics that do not allow easy implementation of research made in other settings (Quiñones et al., 2014). It is one of the most genetically diverse areas having frequencies or polymorphisms not found in other regions. There is a lack of high-quality Latin American population-focused research about the relationship between specific genes and drug response, and, also, there is a lack of knowledge of frequencies. Altogether, there are many disadvantages to implementing pharmacogenetics in clinical practice in Latin America.

Sixteenth articles are included in this issue, eleven original/experimental research, two brief research reports, one review article, one case report, and one opinion, covering different and complementary aspects of the pharmacogenomic research in this region.

Workflows of data-driven modeling and model-driven experimentation have led to the development of in silico algorithms including pharmacogenomics data of disease risk at the patient-population level (Wolkenhauer et al., 2014). In this Research Topic four predictive models based on pharmacogenomics have been developed to identify patients who were suitable for preventive genotyping. Although the models must be validated with a larger number of patients and do not necessarily apply to all populations, they are a very good first approximation to predict the incidence of adverse effects among patients undergoing different therapies in Latin America. Miranda et al. proposed a model that included genetic polymorphisms in addition to clinical records, to predict the tamoxifen response in a population of 162 ER + breast cancer patients (Serral et al.) through an in silico approach, explored the druggable genes of two bacterial pathogens with a relevant impact in Latin America. The model proposed by Varela et al. was based on an integrated in silico analysis of breast and prostate cancer data genes. Finally, the algorithm created by Martinez et al. intended to predict the incidence of infections among patients under chemotherapy treatment.

The PGx of the immunosuppressive drug Tacrolimus (TAC) has been extensively studied, and according to the CPIC guidelines (Birdwell et al., 2015) an increase of starting dose for CYP3A5 expressers is recommended, followed by a therapeutic drug monitoring to guide dose adjustments. Thus, two manuscripts address the issue in Chilean kidney transplantation patients, one in children (Krall et al.), the other in an adult population (Contreras-Castro et al.), for immunosuppressive treatment (cyclosporine and tacrolimus) after transplantation.

The antiretroviral treatment (ART) is generally not well tolerated and most patients present important adverse effects (ADR) that potentially limit treatment adherence or lead to this interruption (Saag et al., 2020). Poblete et al. retrospectively evaluated the UGT1A1*28 and CYP2B6 c.516G > T frequency and their influence on major ADRs in 67 adult HIV patients from Chile, as a starting point to validate in the nearest future CPIC guidelines in Latin America.

Two investigations referred to children with acute lymphoblastic leukemia from different angles. From Mexico, Gándara-Mireles et al. analyzed the frequency distribution and the association between the illness and the most common polymorphisms in ABCG1, NCF4, and CBR3 genes. The influence of TPMT-VNTR polymorphism on 6-MP related hematological toxicity was confirmed by Burgueño-Rodriguez et al. in 130 Uruguayan pediatric patients.

The studies performed in Duchenne Muscular Dystrophy (Luce et al.), cardiovascular disease (Gámez et al.), and severe encephalopathy patients (Kravetz et al.) emphasized the importance of identifying both already known and novel variants to differential diagnosis and patient management. Luce et al. described the mutational spectrum of DMD gene in 400 Argentinian patients with a clinical diagnosis of dystrophinopathy. Gámez et al. reported a significant association between APOB, APOE, and MTHFR polymorphisms and lipid levels, especially in women, among 193 healthy subjects from Chile. Identifying a genetic variant in KCNT1 channel in an Argentinian pediatric patient with a severe encephalopathy was crucial to include quinidine in the treatment regimen as an antiepileptic drug (Kravetz et al.).

Since discovering the non-coding RNA, its clinical relevance has become increasingly important. In particular, inter-individual variability in drug response, both in efficacy and toxicity, could be due to both, variation in miRNA gene sequences and circulating miRNA levels (Latini et al., 2019; Ubilla et al.) found an increase in miRNA-33b-5p levels in hypercholesterolemic patients under atorvastatin therapy and proposed this microRNA as a biomarker to follow the response to statins. Ruiz et al., worried about BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia patients, observed a global decrease of microRNA levels in resistant cells, founding a promiser field for future studies.

On other hand, the biobanks allow access to many well-classified, high-quality samples and establish the indispensable conditions for achieving reproducible research results (Coppola et al., 2019). Vargas and Cobar, express their opinion about creating biobanks and believe that the same requirements will be necessary to obtain pharmacogenetics information and efficient therapeutic responses in Latin America.

Barriers to PGx implementation include a lack of knowledge, training, and confidence among physicians to apply pharmacogenomic tests (Rigter et al., 2020). As such, Undurraga et al. reported on an anonymous online survey addressed to psychiatrists from Chile, observing a low acceptance of PGx tests, but a clear interest from psychiatrists in their potential incorporation into their clinical practice.

We proudly present this research topic which aims to address high-quality pharmacogenetic and pharmacogenomic research with a particular focus on the Latin American population and its needs. The main goal is to increase the information on the clinical implementation and the impact of pharmacogenetics in Latin American patients. Also, collecting experience and project the field in the region, looking for strategies and new perspectives. Furthermore, to potentiate the research among countries in the region.

**AUTHOR CONTRIBUTIONS**

PE: The conception of the Research Topic idea, writing the manuscript. MM: The conception of the Research Topic idea,
writing the manuscript. MR: The conception of the Research Topic idea, writing the manuscript. AL: The conception of the Research Topic idea, writing the manuscript. AL-C: The conception of the Research Topic idea, writing the manuscript. NV: The conception of the Research Topic idea, writing the manuscript. LQ: The conception of the Research Topic idea, writing the manuscript.

REFERENCES

Arbitrio, M., Scionti, F., Di Martino, M. T., Caracciolo, D., Pensabene, L., Tassone, P., et al. (2021). Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice. Clin. Transl Sci. 14 (1), 113–119. Epub 2020 Oct 22. PMID: 33089968; PMCID: PMC7877857. doi:10.1111/cts.12869

Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadee, W., et al. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 Genotype and Tacrolimus Dosing. Clin. Pharmacol. Ther. 98 (1), 19–24. doi:10.1002/cpt.113

Chunnumwat, S., Lu, Z. H., Sukasem, C., Winther, M. D., Capule, F. R., Abdul Hamid, A. A. A. T., et al. (2019). Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives. Public Health Genomics. 22 (3–4), 132–139. doi:10.1159/000502916

Coppola, L., Gianfalone, A., Grimaldi, A. M., Incoronato, M., Bevilacqua, P., Messina, F., et al. (2019). Biobanking in Health Care: Evolution and Future Directions. J. Transl Med. 17 (1), 172. doi:10.1186/s12967-019-1922-3

CPIC (2021). Available at: https://cpicpgx.org/genes-drugs/(Accessed December 06, 2021).

FDA (2021). Available at: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacigenomic-biomarkers-drug-labeling (Accessed December 06, 2021).

Gálvez, A. S., Ramírez, H., Placencia, P., Rojas, C., Urzúa, X., Kalergis, A. M., et al. (2021). Single Nucleotide Polymorphisms in Apolipoprotein B, Apolipoprotein E, and Methylene-tetrahydrofolate Reductase Are Associated With Serum Lipid Levels in Northern ChileanSubjects. A Pilot Study. Front. Genet. 12, 640956. doi:10.3389/fgene.2021.640956

Latini, A., Borgiani, P., Novelli, G., and Cicciacci, C. (2019). miRNAs in Drug Response Variability: Potential Utility as Biomarkers for Personalized Medicine. Pharmacogenomics. 20, 1049–1059. doi:10.2217/pgs-2019-0089

Nicholson, W. T., Formea, C. M., Matey, E. T., Wright, J. A., Girì, J., and Moyer, A. M. (2021). Considerations When Applying Pharmacogenomics to Your Practice. Mayo Clin. Proc. 96 (1), 218–230. doi:10.1016/j.mayocp.2020.03.011

Quiñones, L. A., Lavanderos, M. A., Cayún, J. P., García-Martín, E., Agúndez, J. A., Cárceles, D. D., et al. (2014). Perception of the Usefulness of Drug/gene Pairs and Barriers for Pharmacogenomics in Latin America. Curr. Drug Metab. 15 (2), 202–208. doi:10.2174/1389202015666140202220753

ACKNOWLEDGMENTS

We would like to thank all the authors for their contributions to this topic, to the Latin American Society for Pharmacogenomics and Personalized Medicine (SOLFAGEM) and the Latin American Network for Human Genetics (RELAGH) by their contribution and CYTED by sponsoring this article.

RELAGH (2014). Latin American Network for Human Genetics: Rojas-Martínez A, Giraldo-Ríos A, Jiménez-Arce G, de Vargas AF, Giugliani R. RELAGH - The challenge of having a scientific network in Latin America: An account from the presidents. Genet. Mol. Biol. 37 (1 Suppl. 1), 305–309. doi:10.1590/s1415-47572014000200017

RELIVAF-CYTED (2021). Available at: http://www.cyted.org/es/relivaf (Accessed December 06, 2021).

Rigter, T., Jansen, M. E., de Groot, J. M., Janssen, S. W. J., Rodenburg, W., and Cornel, M. C. (2020). Implementation of Pharmacogenomics in Primary Care: A Multi-Stakeholder Perspective. Front. Genet. 11 (10), 10. doi:10.3389/fgene.2020.00101

Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., et al. (2020). Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA. 324 (16), 1651–1669. doi:10.1001/jama.2020.17025

SOLFAGEM (2021). Latin American Society for Pharmacogenomics and Personalized Medicine. Available at: www.solfagem.org (Accessed December 06, 2021).

U-PGx (2021). Available at: http://upgxe.eu/(Accessed December 06, 2021). Wolkenhauer, O., Auffray, C., Brass, O., Clairambault, J., Deutsch, A., Drasdo, D., et al. (2014). Enabling Multiscale Modeling in Systems Medicine. Genome Med. 6 (3), 21. doi:10.1186/gm538

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Esperón, Martínez, Redal, Lazarowski, López-Cortés, Varela and Quiñones. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.